Should You Ride the Momentum With this S&P ETF?
Investing in the S&P 500 can be tricky these days because a few top stocks can account for a big chunk of many exchange-traded funds (ETFs) that track the index due to their significant market caps. But one fund which invests in the index in an alternative way is the Invesco S&P 500 Momentum ETF (NYSE Arca:SPMO). As its name suggests, it relies on a momentum index to determine which stocks to invest in. There are 100 holdings in the ETF and the top three stocks right now are Amazon (NASDAQ:AMZN), Nvidia (NASDAQ:NVDA), and Meta Platforms (NASDAQ:META), which collectively make up more than 26% of fund’s total weight. Over the past 12 months, the momentum fund has outperformed the S&P 500, achieving gains of 29% while the broad index has risen by around 18% over the same time frame. And if you stretch the period out to five years, then the gap is even wider, with the momentum ETF climbing by 128%, dwarfing the S&P 500’s gains of 85%. While it may seem like a potentially volatile fund, it is only reconstituted and rebalanced twice a year. And with an expense ratio of 0.13%, the ETF’s fees aren’t all that high, either. If you want to invest in the top stocks in the S&P 500, this may potentially be a better option to consider than funds which simply base their weightings on market cap. By focusing on momentum and having a smaller group of holdings, investors may continue to generate market-beating returns with this ETF.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


